Explore our trials
May 10, 2023
SYMBYX Biome, an Australian med-tech business, today announced encouraging results from a Sydney Adventist Hospital (commonly known as the San) trial. These results are the six month follow- up results from a triple-blinded, randomised controlled trial run by the San which investigated the efficacy of the SYMBYX Neuro, a new red/infrared light therapy helmet device on People with Parkinson’s (PWP).
March 17, 2023
SYMBYX, an Australian medtech company developing light therapies for intractable disease conditions, today announced the results of a Sydney Adventist Hospital (commonly known as the San) triple-blinded, randomised controlled trial investigating the effects of a new red/infrared light therapy helmet on patients living with Parkinson’s Disease.
April 22, 2022
SYMBYX, the Australian medical laser company with the world’s first non-pharmaceutical therapy for Parkinson’s, today announced the start of a ground-breaking clinical trial of laser light therapy (photobiomodulation or PBM) on young adults suffering from IBD.
SYMBYX will begin a major clinical trial in Canada using its proprietary treatment system. It's the first Canadian study to examine efficacy of treatment on Parkinson’s symptoms
SYMBYX, an Australian med-tech company developing laser light therapies to reduce Parkinson’s symptoms, said it welcomed the publication of key findings from its Adelaide clinical trial in the leading BMC Neurology Journal.